The iShares Neuroscience and Healthcare ETF (IBRN) seeks to track an index focused on companies developing neuroscience-based treatments and healthcare technologies. This specialized healthcare ETF targets firms advancing brain research, neurological therapies, and related medical innovations within the global healthcare sector.
How It Works
IBRN uses a passively managed approach to replicate its underlying neuroscience and healthcare index through market-capitalization weighting of constituent companies. The fund focuses on pharmaceutical companies, biotechnology firms, and medical device manufacturers specifically engaged in neuroscience research and development. Rebalancing occurs quarterly to maintain index alignment, with holdings concentrated in companies developing treatments for neurological disorders, brain health technologies, and related therapeutic areas.
Key Features
- Highly specialized focus on neuroscience subset of healthcare, offering targeted exposure unavailable in broad healthcare ETFs
- Launched in 2022 to capitalize on growing investment in brain research and neurological treatment development
- Zero expense ratio currently listed, though this may reflect temporary fee waiver or data unavailability for new fund
Risks
- This ETF can lose significant value if neuroscience drug trials fail or regulatory approvals are denied, common in biotech investing
- Concentrated sector exposure means the fund lacks diversification, potentially experiencing 40-60% declines during healthcare sector downturns
- As a new fund launched in 2022, limited track record and low assets under management create liquidity and performance uncertainty
Who Should Own This
Best suited as a satellite holding (5-15% of portfolio) for aggressive investors with 3-7 year time horizons seeking targeted healthcare exposure. High risk tolerance required due to biotech volatility and sector concentration. Appropriate for investors bullish on neuroscience innovation and comfortable with speculative healthcare investments.